| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > PR > Publicity: A Financial Planner's Best Marketing Friend |
|
Main Subject - Publicity: A Financial Planner's Best Marketing Friend
There’s an old African proverb: “If you think you are too small to make a difference, try sleeping in a closed room with a mosquito.” There’s a message here fo According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product r financial planners who want to get free publicity exposure, and use it as a smart marketing tool to grow their practice. Actually, two messages: --You don’t n ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ed to be a big name to get big-time, business-building publicity. --Publicity is a powerful and well-suited way tool for financial planners to get their story o lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. t. In fact publicity, being essentially free, often packs far more punch dollar for dollar than advertising or direct mail for smaller businesses. It raises vis here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe bility, enhances credibility, and provides the best shot, for the buck, at lifting a business to the next level of growth. In the competitive marketplace, publi d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro city is the great equalizer. You win – and beat out bigger rivals for free media space – by being smarter, not by spending more. Smaller companies outscore giant ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc in free media coverage every day -- simply by being more resourceful, effective, and proactive in publicity. With advertising or direct mail, the only way to ge easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi more exposure is to spend more. There’s another crucial advantage to publicity. Those advertising dollars – and it’s great if you have them – buy you visibilit nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically . But publicity earns you credibility¬ – if professional journalists have selected your story to present to their audience, most people believe, your product or and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ service must be good. Smart businesspeople use that publicity to gain more recognition, credibility, and market share. It opens doors to new business, new finan ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ing, new markets – to any audience that responds favorably, as most people and institutions do, to favorable media coverage. How do publicity-successful financi ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a l planners do it? They just learn how to give media people what they need to create great stories. In publicity the coin of the realm – the ticket to success -- dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod is good ideas and creativity, not dollars. Any company, regardless of size, can get significant media attention. Financial planners are full of information that cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin clients need and pay for: How to negotiate taxes and handle finances. How to protect assets. How to start and run a business. The media never stop running stori tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen s on these topics – and all those articles quote experts like you! Look closely at the pages of the major business and personal finance press: sprinkled heavily t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel n there, along with representatives of the industry giants, are scads of quotes from solo and small firm financial planners. Why not you? Cumulatively, this pub ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust icity is a powerful business-building tool. And it’s there for the getting. It just takes a little work in mastering the knack of how to press the right buttons y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products that get the media paying attention. Fortunately, media savvy is like any other resource. It can be bought or rented (by hiring a staffer or retaining an agency . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ; it can be taught, learned, and developed internally. Any of these routes is far cheaper than advertising. For the financial planner, publicity is a lot like t elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip at stone David slapped into his slingshot when he took on Goliath. Affordable. Accessible. And, when aimed properly, way more effective than more expensive tools tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Executive ESP: A Pathway to Success! Department Store Buyer Becomes Interior Designer
|